Shanghai RAAS Blood Products (002252.SZ) Earnings Analysis

Shanghai RAAS Blood Products (002252.SZ) next reports earnings on 2026-08-25, consensus EPS 0.09 CNY. Last quarter (2026-03-27) it missed with EPS 0.0161 CNY vs 0.09 CNY est (-82.1%). It has beaten estimates in 0/6 recent quarters (0%). Trailing P/E 25.52.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 002252.SZ next report earnings?

Next earnings date2026-08-25
Consensus EPS estimate0.09 CNY
Revenue estimate2.33B

002252.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-270.0161 CNY0.09 CNY-82.1%Miss
2025-10-270.067 CNY0.08 CNY-16.2%Miss
2025-08-290.06964 CNY0.0995 CNY-30%Miss
2025-04-270.09 CNY0.1 CNY-10%Miss
2025-04-170.05 CNY0.09 CNY-44.4%Miss
2024-10-280.09 CNY0.1 CNY-10%Miss

Beat rate: 0/6 (0%) over reported quarters with consensus data.

002252.SZ valuation and analyst view

Trailing P/E25.52
Trailing EPS0.20136 CNY
Price / book1.04
Dividend yield0.94%
Market cap34.15B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Shanghai RAAS Blood Products (002252.SZ)'s next earnings date?

Shanghai RAAS Blood Products is next scheduled to report on 2026-08-25, with a consensus EPS estimate of 0.09 CNY and revenue estimate of 2.33B.

Did 002252.SZ beat earnings last quarter?

In its 2026-03-27 report, 002252.SZ posted EPS of 0.0161 CNY versus a 0.09 CNY estimate — a miss of 82.1%.

What is 002252.SZ's earnings track record?

Over the last 6 reported quarters with consensus data, 002252.SZ beat estimates 0 times (0%).

What is 002252.SZ's current P/E ratio and EPS?

002252.SZ trades at a trailing P/E of 25.52 on trailing EPS of 0.20136156110002973 CNY.

What do analysts rate 002252.SZ?

002252.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.